UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-Q ___________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Route 206 & Province Line Road, Princeton, New Jersey 08543 (Address of principal executive ...

Bristol Myers Squibb (BMY) reported $11.89 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 8.4%. EPS of $1.80 for the same period compares to $2.00 a year ago.The reported revenue represents a surprise of +5.07% over the Zacks Consensus Estimate of $11.32 billion. With the consensus EPS estimate being $1.49, the EPS surprise was +20.81%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations ...

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.81%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.64 per share when it actually produced earnings of $2.07, delivering a surprise of 26.22%.Over the last four qua ...

Exhibit 99.1 istol Myers Squibb® Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth • Third Quarter Revenues were $11.9 Billion, increasing 8% (+10% Adjusting for Foreign Exchange) • Growth Portfolio Revenues were $5.8 Billion, increasing 18% (+20% Adjusting for Foreign Exchange) • GAAP EPS was $0.60 and Non-GAAP EPS was $1.80; Includes Net Impact of $(0.09) Per Share for ...

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Bristol Myers Squibb on Thursday reported third-quarter earnings and revenue that blew past Wall Street's expectations thanks to its blockbuster blood thinner Eliquis and a portfolio of drugs it expects to deliver longterm growth. The pharmaceutical giant also raised its full-year revenue guidance for the year, expecting sales to increase by more than 5%. Bristol Myers ...

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report third-quarter 2024 results on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $11.3 billion and $1.50 per share, respectively. | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|-------| | Magnitude Consensus Estimate Trend (60 Days) | Q1 | Q2 | F1 | F2 | | Current | 1.50 | 1.54 | 0.72 | 7.05 | | 7 Days Ago | 1.52 | 1.54 | 0.74 | 7.05 | | ...

Wall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.50 per share in its upcoming release, pointing to a year-over-year decline of 25%. It is anticipated that revenues will amount to $11.3 billion, exhibiting an increase of 3% compared to the year-ago quarter. The current level reflects an upward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraise ...

Founder of Dividend Mantra. Founder of Mr. Free At 33. Co-Founder of Dividends & Income. I started blogging about my journey to financial independence back in 2011. By living well below my means and intelligently investing my hard-earned capital, I went from below broke at age 27 to financially free at 33 years old. I regularly create content on dividend growth investing, living off of dividends, undervalued high-quality dividend growth stocks, high-yield situations, and other long-term investment opportuni ...

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today! I initiated coverage of Bristol Myers Squibb Company (NYSE: BMY ) stock in late March 2024 with a "Buy" rating. At the time, I cited that the company's growth potential wasn't exactly what made it worth buying, but Daniel Sereda is chief investment analyst at a fam ...

Bristol Myers Squibb (BMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syste ...